Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute STelevation myocardial infarction Abstract Purpose: Circulating levels of visfatin, a ubiquitous adipokine, may reflect both the severity of plaque as well as degree of plaque stabilization in acute myocardial injury. The purpose of this study was to test whether the level of visfatin is associated with the occurrence of major adverse cardiovascular events (MACEs) in patients with acute ST-elevation myocardial infarction (STEMI).
Atherosclerosis is widely accepted as a chronic inflammatory disease that is initiated by different vascular and extravascular sources [1] . On the site of the atherosclerotic plaque, the intima is infiltrated with activated macrophages and T lymphocytes, both of which produce and secrete cytokines to drive the inflammatory process [2] . Acute ST-elevation myocardial infarction (STEMI) is a severe cardiac event resulting from the rupture of a vulnerable atherosclerotic plaque in the coronary artery. In acute STEMI, large numbers of inflammatory cells and cytokines are released into circulation; this accelerates the development of adverse events [3] . Cytokines such as leptin, adiponectin, resistin, tumor necrosis factor (TNF)-α and interleukin (IL)-6 play an important role in the pathogenesis of major adverse cardiovascular events (MACEs) [4] [5] [6] .
Visfatin, also known as pre-B-cell colony-enhancing factor, is a 52 to 55 kDa protein that is suggested to be highly prevalent in visceral fat cells. Visfatin was originally isolated as a secreted factor that synergizes with IL-7 and stem cell factors to promote the growth of B-cell precursors [7, 8] . Because it is primarily secreted from adipose tissue, visfatin has been studied as a harmful, pro-inflammatory agent in obesity-induced metabolic and cardiovascular diseases [9, 10] . Previous reports have suggested that visfatin is an inflammatory protein associated with plaque destabilization, atherosclerosis, and acute coronary syndrome (ACS) [11, 12] . In addition, previous evidence has indicated that visfatin, at doses measurable in ACS patient plasma, induces a procoagulant phenotype in human coronary endothelial cells by promoting tissue factor (TF) expression and suggested that visfatin might play an active role in atherothrombotic disease [13] . Furthermore, our previous studies showed that plasma visfatin levels are associated with infarctrelated artery (IRA) occlusion and that increased plasma visfatin may be closely related to the degree of myocardial damage [14, 15] . Moreover, study showed elevated visfatin plasma concentrations in Iranian patients with acute myocardial infarction (AMI) and suggested a possible close relationship between visfatin, chronic inflammation and the development of atherosclerosis [16] . Although there are data to demonstrate that visfatin might be a marker of increased cardiovascular risk [17] , the role of visfatin in the long-term prognostication of STEMI patients undergoing percutaneous coronary intervention (PCI) treatment is still unclear. The aim of this research was to evaluate the relationship between plasma visfatin levels and clinical outcomes in Chinese patients with STEMI who were undergoing PCI.
Methods

Study population
We prospectively enrolled 1,011 consecutive patients who were admitted to our institute between June 2006 and June 2011 due to chest pain. Among these patients, 399 were confirmed to have stable angina, 172 had unstable angina, 242 had NSTEMI and 198 had acute STEMI. Within 12 h of symptom onset, all patients were treated at the Department of Emergency or Cardiovascular Clinic at E-Da Hospital, Kaohsiung, Taiwan (Figure 1 ). Physical examination and laboratory findings of patients with acute STEMI showed prolonged chest pain (>30 min), typical increase in circulating biochemical markers (troponin-I and CK-MB/CPK) with ischemic symptoms lasting for ≥ 30 minutes and an ST-segment elevation of ≥ 2.0 mm in ≥ 2 contiguous electrocardiographic leads. These acute STEMI patients were treated with primary percu- taneous coronary intervention (PPCI) within 12 h of symptom onset. Individuals who had conditions mimicking acute ST elevation not accompanied by occluded coronary arteries and infarct-related artery (IRA) plaque rupture lesions such as coronary spasm, cardiac emboli, myocarditis or Takotsubo syndrome were not included in our study. In addition, the present study did not include patients with a history of malignancy, neoplastic or hepatic infectious disease or autoimmune disease, peripheral atherosclerosis, steroid use or any surgical procedure in the preceding 6 months. Written informed consents were obtained from the patients before enrollment. The study was conducted in agreement with the guidelines approved by the Human Research Ethics Committee at our hospital.
Patient demographic data, clinical characteristics, and current medications were recorded by two independent observers at the time of admission, with special attention given to cardiovascular risk factors and co-morbidities. Age, gender, history of smoking, hyperlipidemia, arterial hypertension, type 2 diabetes, CAD, myocardial infarction (MI) and stroke were also assessed. Interviews, physical examinations, and urinalyses were conducted. Data were evaluated for interobserver agreement on the day of patient discharge; if discrepancies were found, the patient was re-evaluated by both investigators until consensus was reached. Undiagnosed diabetes at admission was detected by measuring fasting blood glucose and hemoglobin A1c (HbA1c) levels and undiagnosed hypertension was detected by measuring blood pressure repeatedly when patients were in the hospital.
Laboratory Measurements
For all patients, venous peripheral blood samples were obtained upon admission for measuring visfatin levels. Blood samples were collected in tubes containing dipotassium ethylenediaminetetraacetic acid (EDTA) and plasma samples were maintained at -80°C for subsequent assays. Plasma levels of triglycerides, total cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), creatinine and glucose were measured using standard commercial methods on a parallel-multichannel analyzer (7170A; Hitachi, Tokyo, Japan), as described previously [18] . Serum levels of cardiac enzymes (creatine kinase [CK] and the CK-MB fraction) and troponin-I levels were measured every 4 h on the first day and every 24 h on the following 3 days using standardized methods. The concentration of plasma visfatin was determined using a commercial enzyme immunoassay (EIA) kit (Phoenix Pharmaceuticals, Belmont, CA) according to our previous report [19] . The detection limit of this assay was 0.1 ng/ml. Plasma C-reactive protein (CRP) level was measured using a high-sensitivity method (IMMAGE; Beckman Coulter, Immunochemistry Systems, Brea, CA) with a detection limit of 0.2 mg/L. Intra-assay coefficients of variation were 4.0%-7.3% for visfatin and 4.2%-8.7% for high-sensitivity CRP (hs-CRP). Samples were measured in duplicate in a single experiment. Hyperglycemia was defined as a glucose level > 126 mg/ dl [20] , and renal insufficiency was defined as an estimated glomerular filtration rate (calculated by the MDRD formula) of <60 mL/min/1.73 m 2 on admission [21] .
Follow-up and definition of endpoints
Patients with acute STEMI were followed-up after admission using a standardized protocol that included outpatient visits, telephone contacts and the recording of recurrent cardiac events. The endpoints were the composite occurrence of MACEs, including death and nonfatal outcomes; i.e., recurrent myocardial infarction (re-MI), clinically driven target lesion revascularization (TLR) (within the stent + 5 mm in both proximal and distal directions) or readmission due to advanced heart failure (defined as a hospital readmission for NYHA class IV heart failure).
Death was defined as all causes of death. Re-MI was defined by the presence of recurrent ischemic symptoms or electrocardiographic changes accompanied by a CK-MB concentration that was more than twice the upper limit of the normal range or more than 50% higher than the previous value measured during hospitalization. Advanced heart failure requiring readmission was diagnosed on the basis of clinical signs, symptoms and chest radiographic findings [22] .
Statistical analysis
Data normality was analyzed using the Kolmogorov-Smirnov test. Continuous, normally distributed variables are presented as mean ± SD. Statistical differences in variables were compared using unpaired Student's t-tests for normally distributed variables. Categorical variables were recorded as frequencies and percentages, and inter-group comparisons were analyzed using the chi-square test or Fisher's exact test. Since the distributions of serum CK-MB, troponin-I, triglycerides, plasma hs-CRP and visfatin were skewed, logarithmically transformed values were used for statistical analysis. Cumulative event curves were plotted using the Kaplan-Meier method and compared using log-rank tests. Univariate Cox proportional hazards regression analysis was conducted to assess an unadjusted association between high visfatin and MACEs. Multivariate analysis with a Cox proportional hazards regression method Hung et al. Visfatin and major adverse cardiovascular events was used to assess the independent association between predictors and MACEs. HRs and 95% confidence intervals (CIs) were calculated. The optimal cutoff point for visfatin as a predictor for composite occurrence of MACEs was calculated by receiving operating characteristics (ROC) analysis. A p-value less than 0.05 was considered statistically significant. All statistical analyses were performed using SAS statistical software, version 8.2 (SAS Institute Inc., Cary, NC).
Results
Among 198 consecutive STEMI patients, thirteen patients were excluded from the study: seven whose duration from symptom onset to PPCI treatment was >12 h, two who had no significant stenosis of the culprit lesion (<50%) and four whose collected blood samples were missing. The final study population included 185 patients (143 men and 42 women; age, 64 ± 13 years) ( Figure 1 ). Medical history related to coronary heart disease included diabetes mellitus in 37.8% patients, hypertension in 60.0% patients, hyperlipidemia in 73.5% patients, and smoking in 31.4% patients ( Table 1) .
All patients received clinical follow-up, with a median duration of 8 months (interquartile range: 2-20 months). During the follow-up period, the incidence of death due to all causes was 10.3% (19 of 185 patients). Among nonfatal outcomes, the incidence of advanced heart failure was 3.2% (6 of 185 patients), TLR was 16.2% (30 of 185 patients) and re-MI was 1.1% (2 of 185). The characteristics of the patients with and without MACEs are presented in Table 2 . Patients with MACEs were older, had a higher rate of both diabetes mellitus and previous MI and presented more commonly with Killip class II-IV (all p < 0.05). The creatinine and visfatin levels were higher in patients with MACEs than in those without MACEs (all p < 0.05).
In the univariate Cox proportional hazards regression analysis, visfatin was associated with composite MACEs (unadjusted relative risk (RR), 1.01; 95% confidence Interval (95% CI), 1.00-1.02; p = 0.041), but not with all causes of mortality (unadjusted RR, 2.44; 95% CI, 0.92-7.62; p = 0.074). Other variables found to be associated with MACEs in the univariate analysis were age (unadjusted RR, 3.24; 95% CI, 1.90-5.54; p < 0.001), heart rate >100 beats/minute (unadjusted RR, 3.90; 95% CI, 2.06-7.00; p = 0.0001), renal insufficiency (unadjusted RR, 3.03; 95% CI, 1.60-6.24; p = 0.0004) and Killip class II-IV (unadjusted RR, 5.56; 95% CI, 2.43-14.99; p < 0.001) ( Table 3) . To determine independent predictors of MACEs, multivariate Cox proportional hazards regression analysis was adjusted for age, sex, blood pressure, hs-CRP, troponin I, visfatin, heart rate >100 beats/min, renal insufficiency, hyperglycemia, Killip class II-IV, anterior infarct, lateral infarct and inferior infarct, and showed that plasma visfatin and age were statistically significant independent predictors of Heart rate (beats) 85 ± 16
Fasting glucose (mmol/L) 9.3 ± 4.5
Total cholesterol (mmol/L) 4.7 ± 1.0
Triglyceride (mmol/L) 1.7 ± 1.0
Creatinine (umol/L) 122.0 ± 68.6
Troponin I peak (ng/ml) 125.5 ± 170.5
CK-MB peak (ng/ml) 203. The overall mean level of visfatin was 20.8±19.1 ng/ml. Patients were divided into three groups based on the low, medium and high plasma visfatin levels. Kaplan-Meier analysis revealed that the occurrence of composite MACEs was the highest in the high plasma visfatin level group (p = 0.030; Figure 2) . The ROC curve for detection of MACEs revealed an area under the curve of 0.60 (95% CI: 1.23-3.89, p = 0.039) for visfatin level. A visfatin level of >14.5 ng/ml was associated with MACEs, with a sensitivity of 70.2%, specificity of 53.9% (Figure 3) . In addition, patients were divided into two groups based on the threshold of plasma visfatin, the incidence of composite MACEs was found to be significantly higher in the high visfatin group (>14.5 ng/ml) than in the low visfatin group (≤14.5 ng/ml; 39.8% versus 20.7%, p = 0.005; Table 4 ). Furthermore, the incidence of all causes of mortality and TLR were also significantly higher in the high visfatin group (16.3% versus 3.5%, p = 0.004 and 21.4% versus 10.3%, p = 0.041, respectively). The frequency of total non-fatal outcomes, advance heart failure and re-MI was the same between the two groups ( Table 4) .
Discussion
The present findings indicate that among patients with acute STEMI, a high plasma visfatin level measured upon hospital admission is associated with composite MACEs. Patients with high plasma visfatin were significantly associated with higher rates of death and TLR than were patients with low plasma visfatin. These results suggest that a high plasma visfatin level at the time of admission has a deleterious influence in patients with acute STEMI.
Visfatin acts as a cytosolic enzyme involved in nicotinamide adenine dinucleotide synthesis, which has been suggested to play a role in inflammatory states and vascular smooth muscle cell maturation, indicating possible involvement in vascular pathology [23] . Interestingly, this adipokine has been shown to be produced by immune cells such as neutrophils and macrophages usually involved in the pathophysiology of acute coronary events too [7, 24] . Specifically, it has been demonstrated that visfatin contributes in promoting inflammation because it induces the expression of proinflammatory molecules such as TNF-α, IL1-β and IL-6 in leucocytes. These inflammatory molecules, in turn, are able to upregulate visfatin expression [25] , creating a vicious circle operating in inflammatory cells within atherosclerotic lesions and potentially responsible of plaque destabilization. Moreover, studies have also showed that visfatin increases monocyte matrix metalloproteinase-9 (MMP-9) activity in monocytic THP-1 cells and is thought to induce weakening of arterial walls, thus potentially contributing to destabilization and rupture of atherosclerotic plaques [12, 26] . Our previous study demonstrated that visfatin expressed in monocytes and neutrophils and increased their reactivity in male acute STEMI patients [27] . Takebayashi et al. observed a significant negative correlation between visfatin and flow-mediated vasodilatation, suggesting that visfatin is related to impaired endothelial function [28] . Visfatin can promote luded adjus fatin, heart a, Killip cla ct. RR, relat stment for age, sevascular smooth muscle inflammation and is associated with a potential role in vascular dysfunction [29] and carotid atherosclerosis [17] . A previous study also indicated that visfatin induces TF-mRNA transcription and de novo synthesis of functionally active TF in human coronary artery endothelial cells in culture [13] . These phenomena appear to be regulated through activation of NF-κB pathway [13] . This study gives a newer point of view on the potential role of visfatin in the pathophysiology of ACS. This adipocytokine, besides promoting plaque disruption [12, 30] , might be actively involved in triggering TF-mediated thrombus formation, finally leading to the occurrence of acute coronary events. Taken together, these data might explain why, in the present study, there are significantly more patients with TLR in the high plasma visfatin group. adverse cardiovascular events. mes (recurrent myocardial infarct tion, target FIGURE 2. Kaplan-Meier analysis of event (major adverse cardiovascular events, MACE)-free survival in patients with acute ST-elevation myocardial infarction according to tertiles of plasma visfatin level. A visfatin level of <10 ng/mL was defined as low, 10-22 ng/mL was defined as medium, and >22 ng/mL was defined as high.
These results indicate that visfatin is closely related to cardiovascular damage, which can predict an adverse cardiovascular outcome.
Literature about mechanisms by which visfatin might have a role in STEMI is still scanty. It has been suggested that this adipokine might trigger plaque rupture by accumulating in atherosclerotic plaques where it stimulates monocyte metalloproteinase activity [12] . It has been demonstrated that this molecule could promote another cause of plaque expansion and vulnerability such as angiogenesis [30] . Our previous reports indicated that plasma visfatin levels are associated with infarct-related artery occlusion [14] . Furthermore, mRNA levels of visfatin and BNP were found to be higher in MI mice than in sham-treated mice. Immunohistochemistry analysis showed that visfatin and BNP immunoreactivity is diffusely observable in left ventricular myocytes of the MI mice, suggesting that visfatin level is closely related to myocardial damage [15] . Additionally, elevated plasma visfatin levels are reported to be associated with CAD and ACS even after correction for classic cardiovascular risk factors such as cholesterol, smoking, hypertension, diabetes and obesity [11, 31] . Visfatin expression was found to be increased in patients with unstable coronary plaques and symptomatic carotid lesions [12] . Moreover, higher visfatin levels were observed in individuals with ischemic stroke [32, 33] . An abnormal profile in serum adipokines observed in AMI is related to systemic inflammation and the degree of atherosclerosis, independently of glucose metabolism disturbances, and heralds MACE occurrence in longterm observation [34] . These observations imply that plasma visfatin level is a potential risk factor of atherosclerosis and CAD. Interestingly, this hypothesis was corroborated by the findings of the present study, which showed that elevated visfatin level is associated with an increased risk of composite MACEs in patients with STEMI. In addition, our study also revealed that, after adjustment for covariates, age is a consistent independent predictor for composite MACEs, in agreement with the findings of previous reports [35, 36] .
Some limitations of this study need to be considered. In this follow-up study, an association was observed between plasma levels of visfatin measured upon admission and clinical outcomes; however, the sample size was limited. It may be necessary to repeat this analysis on a larger scale and to investigate the sequential plasma visfatin levels and the association between plasma visfatin changes with prognosis during acute stage to further explore the role of visfatin in patients with STEMI. Additional research is required to determine whether visfatin plays a role in human myocardium regulation and to investigate the mechanism(s) of its increased expression in patients with acute ischemia.
In conclusion, plasma visfatin level consistently acts as an independent predictor of composite MACEs. In addition, patients with both acute STEMI and a high plasma visfatin level upon hospital admission are associated with a higher rate of composite MACEs. These findings suggest that a high plasma visfatin level provides prognostic information in acute STEMI patients.
